At a Glance
Quickcomparison
Dose Range
Larazotide
250 mcg–1000 mcg mcg
BPC-157
250–500 mcg
Frequency
Once daily
Administration
Oral (capsule or tablet)
Subcutaneous injection
Cycle Length
Ongoing/indefinite
4-6 weeks
Onset Speed
Moderate (1-2 weeks)
Evidence Level
Strong human trials (Phase 3 or FDA approved)
Strong preclinical (extensive animal studies)
Efficacy
Benefitratings
Intestinal Barrier Protection
Celiac Disease Management
Safety & Tolerability
Primary Benefit
Secondary Benefit
Additional Benefit
Technical Data
Compoundspecifications
Molecular Formula
C34H59N9O12
Molecular Weight
785.9 g/mol
Half-Life
Unknown - acts primarily as local intestinal barrier regulator rather than systemic drug
Bioavailability
Orally administered; acts locally on intestinal epithelium with minimal systemic absorption
CAS Number
206899-25-6
C62H98N16O22
1419.53 g/mol
4-6 hours
~100% (subcutaneous)
137525-51-0
Protocols
Dosingtiers
standard
0.5 mg
Three times daily (before meals)
12 weeks in trials; ongoing for symptom control
Trial-established dose: in a Phase 2b randomized controlled trial in celiac disease, 0.5 mg three times daily met the primary endpoint with fewer symptoms vs placebo. Notably, the higher 1 mg and 2 mg doses showed no benefit over placebo, so 0.5 mg is the effective dose [6]. Taken before meals as a local intestinal tight-junction regulator [1].
starting
250 mcg
1-2 weeks
A common starting amount in research practice, often injected near the injured area. BPC-157 has no human dose-finding trials, so doses come from animal studies and documented practice [1][2].
250-500 mcg
Twice daily
Commonly used range for tissue and tendon recovery in research practice [1][3].
advanced
500 mcg
6-8 weeks
Upper end used in practice for more demanding acute injuries [1][3].
Applications
Bestsuited for
Managing celiac disease symptoms despite strict gluten avoidance
Larazotide is particularly well-suited for individuals focused on managing celiac disease symptoms despite strict gluten avoidance. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Reducing accidental gluten exposure damage
Larazotide is particularly well-suited for individuals focused on reducing accidental gluten exposure damage. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Restoring digestive comfort and nutrient absorption
Larazotide is particularly well-suited for individuals focused on restoring digestive comfort and nutrient absorption. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Supporting intestinal healing and barrier function
Larazotide is particularly well-suited for individuals focused on supporting intestinal healing and barrier function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Tendon and ligament injuries
Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair
Gut healing
IBS, leaky gut, ulcers, inflammatory bowel conditions - derived from gastric juice, it has a natural affinity for digestive tissue
Muscle injuries
Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression
Joint problems
Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties
Post-surgical recovery
Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms
Safety Profile
Sideeffects
Common
Headache
Nausea
Abdominal Cramping
Fatigue
Uncommon
Transient Diarrhea
Serious
Allergic Reaction
Injection site redness
Mild nausea
Dizziness
Hot/cold sensations
Allergic reaction
Research Status
Safety& evidence
FDA Status
Not FDA approved
Safety Overview
Larazotide (ALX-0061, AT-1001) is a synthetic tight-junction regulator that improved intestinal barrier function in Phase 2 celiac disease trials with favorable safety. The mechanism—zonula occludens-1 modulation—is specific to epithelial tight junctions without broad immunosuppression. Gastrointestinal side effects (nausea, diarrhea, abdominal pain) occur in 10-20% of patients but are typically mild and resolve with dose adjustment or continued exposure. FDA feedback on Phase 3 trials indicated efficacy trends but required additional manufacturing and clinical data before approval consideration.
Contraindications
xKnown hypersensitivity to larazotide or any component
xSevere gastrointestinal obstruction
xActive untreated infections (may require monitoring)
xPregnancy and breastfeeding (limited safety data)
Research compound
BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. No FDA approval exists. Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.
xPregnancy
xBreastfeeding
xActive cancer
xHistory of cancer
Decision Guide
Which isright for you?
Choose Larazotide if...
Managing celiac disease symptoms despite strict gluten avoidance
Reducing accidental gluten exposure damage
Restoring digestive comfort and nutrient absorption
Supporting intestinal healing and barrier function
Choose BPC-157 if...
Injury recovery
Post-surgery healing
Chronic pain management
Gut health